Newcastle Disease Virus As a Vaccine Vector for Development of Human and Veterinary Vaccines

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2016 Jul 8

PMID 27384578

Citations 62

Authors

Shin-Hee Kim

Siba K Samal

Affiliations

Soon will be listed here.

Abstract

Viral vaccine vectors have shown to be effective in inducing a robust immune response against the vaccine antigen. Newcastle disease virus (NDV), an avian paramyxovirus, is a promising vaccine vector against human and veterinary pathogens. Avirulent NDV strains LaSota and B1 have long track records of safety and efficacy. Therefore, use of these strains as vaccine vectors is highly safe in avian and non-avian species. NDV replicates efficiently in the respiratory track of the host and induces strong local and systemic immune responses against the foreign antigen. As a vaccine vector, NDV can accommodate foreign sequences with a good degree of stability and as a RNA virus, there is limited possibility for recombination with host cell DNA. Using NDV as a vaccine vector in humans offers several advantages over other viral vaccine vectors. NDV is safe in humans due to host range restriction and there is no pre-existing antibody to NDV in the human population. NDV is antigenically distinct from common human pathogens. NDV replicates to high titer in a cell line acceptable for human vaccine development. Therefore, NDV is an attractive vaccine vector for human pathogens for which vaccines are currently not available. NDV is also an attractive vaccine vector for animal pathogens.

Citing Articles

Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats.

Parish L, Rele S, Hofmeyer K, Luck B, Wolfe D Vaccines (Basel). 2025; 13(1).

PMID: 39852852 PMC: 11769106. DOI: 10.3390/vaccines13010073.

A novel approach for efficient co-expression of two foreign genes based on the reverse genetic system of Newcastle disease virus.

Lan T, Liu Q, Ge J, Wang Y Front Microbiol. 2025; 15:1442551.

PMID: 39744396 PMC: 11689658. DOI: 10.3389/fmicb.2024.1442551.

Characterizing Host microRNA: Virus Interactions of .

Mears M, Bakre A Viruses. 2024; 16(11).

PMID: 39599862 PMC: 11599118. DOI: 10.3390/v16111748.

Development of a genotype-matched Newcastle disease DNA vaccine candidate adjuvanted with IL-28b for the control of targeted velogenic strains of Newcastle disease virus in Africa.

Amoia C, Chengula A, Hakizimana J, Wambura P, Munir M, Misinzo G Vet Res Commun. 2024; 49(1):33.

PMID: 39585481 PMC: 11588948. DOI: 10.1007/s11259-024-10590-y.

Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects hACE2 TG Mice against Lethal SARS-CoV-2 Infection.

Kim D, Lee J, Lee D, Lee S, Jeong J, Kim J Vaccines (Basel). 2024; 12(8).

PMID: 39204044 PMC: 11359043. DOI: 10.3390/vaccines12080921.

References

Kortekaas J, de Boer S, Kant J, Vloet R, Antonis A, Moormann R . Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine. 2010; 28(27):4394-401. DOI: 10.1016/j.vaccine.2010.04.048. View

Belshe R, Edwards K, Vesikari T, Black S, Walker R, Hultquist M . Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007; 356(7):685-96. DOI: 10.1056/NEJMoa065368. View

Ge J, Deng G, Wen Z, Tian G, Wang Y, Shi J . Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol. 2006; 81(1):150-8. PMC: 1797253. DOI: 10.1128/JVI.01514-06. View

Paldurai A, Kim S, Nayak B, Xiao S, Shive H, Collins P . Evaluation of the contributions of individual viral genes to newcastle disease virus virulence and pathogenesis. J Virol. 2014; 88(15):8579-96. PMC: 4135945. DOI: 10.1128/JVI.00666-14. View

Freeman A, Zakay-Rones Z, Gomori J, Linetsky E, Rasooly L, Greenbaum E . Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2005; 13(1):221-8. DOI: 10.1016/j.ymthe.2005.08.016. View

Carnero E, Li W, Borderia A, Moltedo B, Moran T, Garcia-Sastre A . Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol. 2008; 83(2):584-97. PMC: 2612356. DOI: 10.1128/JVI.01443-08. View

Khattar S, Collins P, Samal S . Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine. 2010; 28(18):3159-70. PMC: 3428038. DOI: 10.1016/j.vaccine.2010.02.051. View

DiNapoli J, Kotelkin A, Yang L, Elankumaran S, Murphy B, Samal S . Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A. 2007; 104(23):9788-93. PMC: 1887550. DOI: 10.1073/pnas.0703584104. View

Xiao S, Nayak B, Samuel A, Paldurai A, Kanabagattebasavarajappa M, Prajitno T . Generation by reverse genetics of an effective, stable, live-attenuated newcastle disease virus vaccine based on a currently circulating, highly virulent Indonesian strain. PLoS One. 2013; 7(12):e52751. PMC: 3528709. DOI: 10.1371/journal.pone.0052751. View

10.

Bukreyev A, Collins P . Newcastle disease virus as a vaccine vector for humans. Curr Opin Mol Ther. 2008; 10(1):46-55. View

11.

Khattar S, DeVico A, LaBranche C, Panda A, Montefiori D, Samal S . Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins. J Virol. 2015; 90(3):1682-6. PMC: 4719621. DOI: 10.1128/JVI.02847-15. View

12.

Panda A, Huang Z, Elankumaran S, Rockemann D, Samal S . Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb Pathog. 2003; 36(1):1-10. PMC: 7125746. DOI: 10.1016/j.micpath.2003.07.003. View

13.

DiNapoli J, Yang L, Samal S, Murphy B, Collins P, Bukreyev A . Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine. 2010; 29(1):17-25. PMC: 3428043. DOI: 10.1016/j.vaccine.2010.10.024. View

14.

DiNapoli J, Nayak B, Yang L, Finneyfrock B, Cook A, Andersen H . Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol. 2009; 84(3):1489-503. PMC: 2812327. DOI: 10.1128/JVI.01946-09. View

15.

Peeters B, de Leeuw O, Koch G, Gielkens A . Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol. 1999; 73(6):5001-9. PMC: 112544. DOI: 10.1128/JVI.73.6.5001-5009.1999. View

16.

Huang Z, Krishnamurthy S, Panda A, Samal S . High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus. J Gen Virol. 2001; 82(Pt 7):1729-1736. DOI: 10.1099/0022-1317-82-7-1729. View

17.

Nakaya T, Cros J, Park M, Nakaya Y, Zheng H, Sagrera A . Recombinant Newcastle disease virus as a vaccine vector. J Virol. 2001; 75(23):11868-73. PMC: 114773. DOI: 10.1128/JVI.75.23.11868-11873.2001. View

18.

Khattar S, Samal S, DeVico A, Collins P, Samal S . Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J Virol. 2011; 85(20):10529-41. PMC: 3187513. DOI: 10.1128/JVI.05050-11. View

19.

Nakaya Y, Nakaya T, Park M, Cros J, Imanishi J, Palese P . Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J Virol. 2004; 78(17):9366-75. PMC: 506935. DOI: 10.1128/JVI.78.17.9366-9375.2004. View

20.

Toro H, Zhao W, Breedlove C, Zhang Z, Yu Q, van Santen V . Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge. Avian Dis. 2014; 58(1):83-9. DOI: 10.1637/10641-081613-Reg.1. View